Press releasePRNewswire
Karyopharm Therapeutics
KPTI · NASDAQ
$0.3586+$0.0126 (+3.64%)TodayMarket closed ·
Prev close $0.346
Latest news
- Press releasePRNewswire
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Press releasePRNewswire
Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO® (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI
- Press releaseGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI
- News
Karyopharm Therapeutics Reports Q2 2026 Results: Full Earnings Call Transcript
- Press releasePRNewswire
Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission
- Press releaseGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI
- Press releasePRNewswire
Karyopharm to Report Second Quarter 2026 Financial Results on August 13, 2026
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI
- Press releaseGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI
- Press releasePRNewswire
Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- News
12 Health Care Stocks Moving In Friday's Intraday Session
- NewsAvi Kapoor
Crude Oil Gains 1%; Apple Shares Tumble After Q3 Results
- NewsAvi Kapoor
Nasdaq Surges 300 Points; Amazon Shares Jump Following Upbeat Earnings
- News
12 Health Care Stocks Moving In Friday's Pre-Market Session
- NewsTanya Rawat
Karyopharm Stock (KPTI) Crashes After Hours: Here's What's Driving the Move
- News
12 Health Care Stocks Moving In Thursday's After-Market Session
- Press releasePRNewswire
Karyopharm Plans to Submit sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis Under Accelerated Approval Pathway
- Press releasePRNewswire
Karyopharm Announces Topline Results from Phase 3 XPORT-EC-042 Trial in Endometrial Cancer
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI
- Press releasePRNewswire
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Press releasePRNewswire
Karyopharm to Participate in Webcast Featuring Endometrial Cancer Key Opinion Leader on June 8, 2026
- Press releasePRNewswire
Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026
- Press releasePRNewswire
Karyopharm to Present Results from Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis in Late-Breaking Oral Presentation at ASCO 2026 with Simultaneous Publication in the Journal of Clinical Oncology
- Press releasePRNewswire
Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Press releasePRNewswire
Karyopharm to Host Investor Conference Call Featuring Expert Perspectives on the Phase 3 SENTRY Trial in Myelofibrosis Following 2026 ASCO Presentation
- Press releasePRNewswire
Karyopharm to Participate at the 2026 Jefferies Global Healthcare Conference
- News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- News
Karyopharm Therapeutics Reports Q1 2026 Results: Full Earnings Call Transcript
- Press releasePRNewswire
Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment
- News
Earnings Scheduled For May 14, 2026
- Press releasePRNewswire
Karyopharm to Participate at Upcoming Investor Conferences
- News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.